未知股票 NKGN 深 沪
已收盘
--
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 --
- 最 低 --
- 昨 收 --
- 总市值 0
- 52周最高 --
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 4528.09万
- 历史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 1
- 风险率 0.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NKGen Biotech expands debt financing with loan amendment
The latest announcement is out from NKGen Biotech ( ($NKGN) ). On January 30, 2...
02-06 06:55
NKGen Biotech Q2 EPS $(0.04) Up From $(0.25) YoY
NKGen Biotech (OTC:NKGN) reported quarterly losses of $(0.04) per share. This is a 84 percent increase over losses of $(0.25) per share from the same period last year.
01-21 06:37
NKGen Biotech Expands Debt Financing Through Note Amendment
NKGen Biotech ( ($NKGN) ) has provided an update. On January 12, 2026, NKGen Bi...
01-17 06:50
NKGen Biotech Secures New Promissory Note Financing
An announcement from NKGen Biotech ( ($NKGN) ) is now available. On January 5, ...
01-10 06:48
Delisting of Securities from The Nasdaq Stock Market
The Nasdaq Stock Market announced on July 11, 2025, that it will delist the securities of multiple companies, including NKGen Biotech, Inc., Aquaron Acquisition Corp., Bannix Acquisition Corp., Avenue Therapeutics, Inc., WinVest Acquisition Corp., IMAC Holdings, Inc., Lytus Technologies Holdings PTV Ltd., Luokung Technology Corp., Aptose Biosciences, Inc., Virpax Pharmaceuticals, Inc., Phoenix Motor Inc., Denali Capital Acquisition Corp., Thunder...
2025-07-11 20:05
NKGen Biotech Announces International and U.S. Expansion of Phase 1/2a Troculeucel Alzheimer’s Trial with Activation of Clinical Sites in Canada and Florida
NKGen Biotech has activated two new clinical trial sites for its Phase 1/2a trial evaluating troculeucel, an autologous NK cell therapy, in moderate Alzheimer’s disease patients. The new sites are the Ottawa Memory Clinic in Canada and AdventHealth Orlando in Florida, USA. These activations expand the trial’s geographic reach, enhancing patient diversity and recruitment efficiency. The Ottawa Memory Clinic will be led by Dr. Richard Bergeron, a r...
2025-06-23 12:05
BRIEF-NKGen Biotech Enters Seventh Amendment To Forward Purchase Agreement Dated Sept 22, 2023
Jan 2 (Reuters) - Nkgen Biotech Inc NKGN.O: NKGEN BIOTECH INC - ENTERS SEVENTH AMENDMENT TO FORWARD PURCHASE AGREEMENT DATED SEPT 22, 2023 NKGEN BIOTECH INC: UNDER AMENDMENT, CO AND SELLER AGREED TO E...
2025-01-03 06:36
NKGen Biotech Awards Stock Options to Executives
The latest announcement is out from NKGen Biotech ( ($NKGN) ). NKGen Biotech, I...
2024-12-13 06:57
NKGen Biotech Secures Key Role in NKMax Deal
NKGen Biotech ( ($NKGN) ) has provided an update. NKGen Biotech has been chosen...
2024-12-03 05:32
NKGen Biotech Faces Delisting Notice Amid Reporting Delay
An announcement from NKGen Biotech ( ($NKGN) ) is now available. NKGen Biotech ...
2024-11-27 05:58
